WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Yuriko Adkins, PhD
- Phone Number: 530-752-9469
- Email: yuriko.adkins@usda.gov
Study Contact Backup
- Name: Ellen Bonnel, PhD
- Phone Number: 530-752-4184
- Email: ellen.bonnel@usda.gov
Study Locations
-
-
California
-
Davis, California, United States, 95616
- USDA, ARS, Western Human Nutrition Research Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Body Mass Index (BMI) 18.5 - 30.9 kg/m2
inadequate total dietary fiber intake defined as:
- Females 18 - 30 years old, less than 28 g/day
- Females 31 - 50 years old, less than 25 g/day
- Females 51+ year old, less than 22 g/day
- Males 18 - 30 years old, less than 34 g/day
- Males 31 - 50 years old, less than 31 g/day
- Males 51+ years old, less than 28 g/day
Exclusion Criteria:
- blood pressure greater than or equal to 140/90 mmHg
- has HIV/AIDS or another disease that affects the immune system
- has any kind of cancer
- inability to lift 30 pounds with assistance (for transporting refrigerated stool containers)
- decline to take an HIV blood test
- pregnant or lactating women
- refusal to take a pregnancy test
- female subjects: refusal to use a method of birth control 1 week prior to the administration of the vaccine, 1 week during the vaccine, and 1 week after the vaccine
- allergy to vaccine components, i.e. thimerosal and enteric-coated capsules
- allergy to oral typhoid vaccine
- use of anti-inflammatory medications, i.e. nonsteroidal anti-inflammatory drugs (NSAID), aspirin, 3 or more times per month
- use of sulfonamides or antibiotics 3 months prior to the receipt of Ty21a vaccine.
- use of anti-hypertensive drugs, i.e. beta blockers, diuretics, calcium channel blockers
- use of anti-malaria drugs, i.e. mefloquine, chloroquine, and proguanil
- use of drugs that affects the immune system, i.e. immunosuppressants, immune-modifying drugs, corticosteroids, i.e. cortisone, prednisone, methylprednisolone, for 2 weeks or longer
- use of biologics, i.e. Lantus, Remicade, Rituxan, Humira, Herceptin, Avastin, Lucentis, Enbrel for 2 weeks or longer
- undergoing cancer treatment with radiation or drugs
- greater than 10 years residence in a typhoid-endemic area
- receipt of typhoid vaccine in the last 5 years
- receipt of any vaccine two weeks prior to receipt of Ty21a vaccine
- individuals at increased risk of developing complications from a live, bacterial vaccine
- history of typhoid fever
- history of primary immune deficiency or autoimmune disease
- history of acute or chronic gastrointestinal (GI) disorder, i.e. Crohn's disease, irritable bowel syndrome, gastric ulcer
- diarrheal illness (defined as passing 3 or more abnormally loose or watery stool in a 24 hour period) or persistent vomiting 2 weeks prior to the study
- history of chronic illnesses, i.e. diabetes, cardiovascular disease, cancer, gastrointestinal malabsorption or inflammatory diseases, kidney disease, autoimmune disorders, HIV, liver disease, including hepatitis B and C
- asthma if taking medication on a daily basis
- recent surgery (within 3 months)
- history of GI surgery
- recent hospitalization (within 3 months)
- fever (within 2 weeks)
- unwillingness to discontinue probiotic, prebiotic, or other supplements (except Recommended Dietary Allowance-level vitamin and mineral supplements), fiber supplements, or food and beverage products containing inulin, chicory root fiber, or maltodextrin during the study
- not having at least one arm vein suitable for blood drawing
- unwilling or uncomfortable with blood draws and stool collections
- regular blood or blood product donation and refusal to suspend donation
- current participation in another research study
- unable to fast for 12-16 hours
- have fewer than 3 bowel movements per week
- consuming one or more servings of added-inulin foods per day over the past month
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Inulin and Ty21a Vaccine
Participants will consume 12 grams/day of inulin for 3 weeks before the administration of the Ty21a vaccine, 1 week during the vaccine, and 1 week after the vaccine for a total of 5 weeks.
|
Consume 12 grams/day of inulin for 5 weeks (Day 9 - 43).
Other Names:
All participants will receive the vaccine.
One capsule is swallowed on alternate days, e.g.
days 30, 32, 34, and 36 for a total of 4 capsules.
Other Names:
|
|
Placebo Comparator: Maltodextrin and Ty21a Vaccine
Participants will consume 12 grams/day of maltodextrin (control) for 3 weeks before the administration of the Ty21a vaccine, 1 week during the vaccine, and 1 week after the vaccine for a total of 5 weeks.
|
All participants will receive the vaccine.
One capsule is swallowed on alternate days, e.g.
days 30, 32, 34, and 36 for a total of 4 capsules.
Other Names:
Consume 12 grams/day of maltodextrin for 5 weeks (Day 9 - 43).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in vaccine-specific antibody-secreting cell response to oral Ty21a typhoid vaccination using the standard 4-dose regimen
Time Frame: Day 26, 37, and 39
|
Measurement of baseline level (Day 26; before first vaccine dose) and post-vaccine, antibody response, Immunoglobulin G (IgG), Immunoglobulin M (IgM) and IgA, 7 and 9 days after the first vaccine dose using the antibody-in-lymphocyte-supernatant (ALS) assay to identify antibody-secreting cells in blood.
Two antigens will be used: Ty21a outer membrane protein and lipopolysaccharide from Salmonella Typhi.
|
Day 26, 37, and 39
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in vaccine-specific serum antibody response to typhoid vaccination
Time Frame: Day 26 and 58
|
Measurement of baseline level (Day 26; before first vaccine dose) and post-vaccine (28 d after first vaccine dose) antibody levels (IgG, IgM, IgA)
|
Day 26 and 58
|
|
Change in vaccine-specific fecal IgA antibody levels from typhoid vaccination
Time Frame: Day 26, 39, and 58
|
Measurement of baseline level (Day 26; before first vaccination dose) and change in fecal antibody levels
|
Day 26, 39, and 58
|
|
Change in plasma cytokines as markers of systemic inflammation
Time Frame: Day 8, 26, 37, 39, and 58
|
Measurement of plasma cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and IL-1beta
|
Day 8, 26, 37, 39, and 58
|
|
Change in plasma acute phase proteins and adhesion molecules
Time Frame: Day 8, 26, 37, 39, and 58
|
Measurement of acute phase reactants, such as C-reactive protein (CRP) and serum amyloid-A (SAA), and intercellular adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1) and vascular endothelial cell adhesion molecule-1 (VCAM-1)
|
Day 8, 26, 37, 39, and 58
|
|
Change in a plasma marker of lipopolysaccharide (LPS) exposure
Time Frame: Day 8, 26, 37, 39, and 58
|
Measurement of plasma LPS-binding protein using an ELISA.
|
Day 8, 26, 37, 39, and 58
|
|
Change in blood monocyte subsets
Time Frame: Day 8, 26, 37, 39, and 58
|
Monocyte subsets will be analyzed using flow cytometry.
|
Day 8, 26, 37, 39, and 58
|
|
Change in plasma short chain fatty acids (SCFA)
Time Frame: Day 8, 26, 37, 39, and 58
|
Plasma SCFA will be measured using liquid chromatography-mass spectrometry (LC-MS).
|
Day 8, 26, 37, 39, and 58
|
|
Change in urinary lactulose and D-mannitol
Time Frame: Day 8, 26, and 37
|
Measurement of lactulose to mannitol ratio, an indicator of intestinal permeability, in urine
|
Day 8, 26, and 37
|
|
Change in fecal microbiome
Time Frame: Period 1: Days 1-7; Period 2: Days 16-25; Period 3: Days 26-36; Period 4: Days 37-43; Period 5: Days 58-65
|
Measurement of relative abundance of colonic bacteria using DNA isolated from stool.
|
Period 1: Days 1-7; Period 2: Days 16-25; Period 3: Days 26-36; Period 4: Days 37-43; Period 5: Days 58-65
|
|
Change in fecal mRNA
Time Frame: Period 1: Days 1-7; Period 2: Days 16-25; Period 3: Days 26-36; Period 4: Days 37-43; Period 5: Days 58-65
|
Total RNA, and specifically, messenger ribonucleic acid (mRNA), will be analyzed from preserved stools.
|
Period 1: Days 1-7; Period 2: Days 16-25; Period 3: Days 26-36; Period 4: Days 37-43; Period 5: Days 58-65
|
|
Change in stool consistency and frequency
Time Frame: Period 1: Days 1-7; Period 2: Days 16-25; Period 3: Days 26-36; Period 4: Days 37-43; Period 5: Days 58-65
|
Measurement of stool consistency using the Bristol stool scale, a medical tool used to classify stool forms into 7 categories, and frequency via self-report in diaries.
|
Period 1: Days 1-7; Period 2: Days 16-25; Period 3: Days 26-36; Period 4: Days 37-43; Period 5: Days 58-65
|
|
Change in GI symptoms
Time Frame: Period 1: Days 1-7; Period 2: Days 16-25; Period 3: Days 26-36; Period 4: Days 37-43; Period 5: Days 58-65
|
Measurement of GI symptoms using a 10-symptom health questionnaire with degree of discomfort ranked in one of four categories (0 absent, 1 mild, 2 moderate, or 3 severe; PMID: 9301412)
|
Period 1: Days 1-7; Period 2: Days 16-25; Period 3: Days 26-36; Period 4: Days 37-43; Period 5: Days 58-65
|
|
Change in fecal pH
Time Frame: Period 1: Days 1-7; Period 2: Days 16-25; Period 3: Days 26-36; Period 4: Days 37-43; Period 5: Days 58-65
|
Measurement of fecal pH using a standard pH meter.
|
Period 1: Days 1-7; Period 2: Days 16-25; Period 3: Days 26-36; Period 4: Days 37-43; Period 5: Days 58-65
|
|
Change in fecal calprotectin
Time Frame: Period 1: Days 1-7; Period 2: Days 16-25; Period 3: Days 26-36; Period 4: Days 37-43; Period 5: Days 58-65
|
Measurement of calprotectin will be done by ELISA
|
Period 1: Days 1-7; Period 2: Days 16-25; Period 3: Days 26-36; Period 4: Days 37-43; Period 5: Days 58-65
|
|
Change in fecal SCFA
Time Frame: Period 1: Days 1-7; Period 2: Days 16-25; Period 3: Days 26-36; Period 4: Days 37-43; Period 5: Days 58-65
|
Measurement of SCFA will be done by gas chromatography-mass spectrometry (GC-MS.)
|
Period 1: Days 1-7; Period 2: Days 16-25; Period 3: Days 26-36; Period 4: Days 37-43; Period 5: Days 58-65
|
|
Change in fecal metabolites
Time Frame: Period 1: Days 1-7; Period 2: Days 16-25; Period 3: Days 26-36; Period 4: Days 37-43; Period 5: Days 58-65
|
Measurement of bile acids and other metabolites will be measured
|
Period 1: Days 1-7; Period 2: Days 16-25; Period 3: Days 26-36; Period 4: Days 37-43; Period 5: Days 58-65
|
|
Change in fecal secretory total immunoglobulin A (sIgA)
Time Frame: Period 1: Days 1-7; Period 2: Days 16-25; Period 3: Days 26-36; Period 4: Days 37-43; Period 5: Days 58-65
|
Measurement of total fecal sIgA using ELISA.
|
Period 1: Days 1-7; Period 2: Days 16-25; Period 3: Days 26-36; Period 4: Days 37-43; Period 5: Days 58-65
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Mary Kable, PhD, USDA, ARS, Western Human Nutrition Research Center
- Principal Investigator: Danielle Lemay, PhD, USDA, ARS, Western Human Nutrition Research Center
- Principal Investigator: Ryan Snodgrass, PhD, USDA, ARS, Western Human Nutrition Research Center
- Principal Investigator: Bess Caswell, PhD, USDA, ARS, Western Human Nutrition Research Center
Publications and helpful links
General Publications
- Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PG, Neyrinck AM, Bindels LB, de Vos WM, Gibson GR, Thissen JP, Delzenne NM. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut. 2013 Aug;62(8):1112-21. doi: 10.1136/gutjnl-2012-303304. Epub 2012 Nov 7.
- Meyer D, Stasse-Wolthuis M. The bifidogenic effect of inulin and oligofructose and its consequences for gut health. Eur J Clin Nutr. 2009 Nov;63(11):1277-89. doi: 10.1038/ejcn.2009.64. Epub 2009 Aug 19.
- Costabile A, Kolida S, Klinder A, Gietl E, Bauerlein M, Frohberg C, Landschutze V, Gibson GR. A double-blind, placebo-controlled, cross-over study to establish the bifidogenic effect of a very-long-chain inulin extracted from globe artichoke (Cynara scolymus) in healthy human subjects. Br J Nutr. 2010 Oct;104(7):1007-17. doi: 10.1017/S0007114510001571. Epub 2010 Jul 1.
- Holscher HD, Bauer LL, Gourineni V, Pelkman CL, Fahey GC Jr, Swanson KS. Agave Inulin Supplementation Affects the Fecal Microbiota of Healthy Adults Participating in a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. J Nutr. 2015 Sep;145(9):2025-32. doi: 10.3945/jn.115.217331. Epub 2015 Jul 22.
- Kolida S, Meyer D, Gibson GR. A double-blind placebo-controlled study to establish the bifidogenic dose of inulin in healthy humans. Eur J Clin Nutr. 2007 Oct;61(10):1189-95. doi: 10.1038/sj.ejcn.1602636. Epub 2007 Jan 31.
- Menne E, Guggenbuhl N, Roberfroid M. Fn-type chicory inulin hydrolysate has a prebiotic effect in humans. J Nutr. 2000 May;130(5):1197-9. doi: 10.1093/jn/130.5.1197.
- Micka A, Siepelmeyer A, Holz A, Theis S, Schon C. Effect of consumption of chicory inulin on bowel function in healthy subjects with constipation: a randomized, double-blind, placebo-controlled trial. Int J Food Sci Nutr. 2017 Feb;68(1):82-89. doi: 10.1080/09637486.2016.1212819. Epub 2016 Aug 5.
- Petry N, Egli I, Chassard C, Lacroix C, Hurrell R. Inulin modifies the bifidobacteria population, fecal lactate concentration, and fecal pH but does not influence iron absorption in women with low iron status. Am J Clin Nutr. 2012 Aug;96(2):325-31. doi: 10.3945/ajcn.112.035717. Epub 2012 Jun 27.
- Huda MN, Lewis Z, Kalanetra KM, Rashid M, Ahmad SM, Raqib R, Qadri F, Underwood MA, Mills DA, Stephensen CB. Stool microbiota and vaccine responses of infants. Pediatrics. 2014 Aug;134(2):e362-72. doi: 10.1542/peds.2013-3937. Epub 2014 Jul 7.
- Huda MN, Ahmad SM, Alam MJ, Khanam A, Kalanetra KM, Taft DH, Raqib R, Underwood MA, Mills DA, Stephensen CB. Bifidobacterium Abundance in Early Infancy and Vaccine Response at 2 Years of Age. Pediatrics. 2019 Feb;143(2):e20181489. doi: 10.1542/peds.2018-1489.
- Zuckerman JN, Hatz C, Kantele A. Review of current typhoid fever vaccines, cross-protection against paratyphoid fever, and the European guidelines. Expert Rev Vaccines. 2017 Oct;16(10):1029-1043. doi: 10.1080/14760584.2017.1374861.
- Fiorentino M, Lammers KM, Levine MM, Sztein MB, Fasano A. In vitro Intestinal Mucosal Epithelial Responses to Wild-Type Salmonella Typhi and Attenuated Typhoid Vaccines. Front Immunol. 2013 Feb 12;4:17. doi: 10.3389/fimmu.2013.00017. eCollection 2013.
- Salerno-Goncalves R, Galen JE, Levine MM, Fasano A, Sztein MB. Manipulation of Salmonella Typhi Gene Expression Impacts Innate Cell Responses in the Human Intestinal Mucosa. Front Immunol. 2018 Nov 1;9:2543. doi: 10.3389/fimmu.2018.02543. eCollection 2018.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Negative Bacterial Infections
- Enterobacteriaceae Infections
- Salmonella Infections
- Pathological Conditions, Signs and Symptoms
- Inflammation
- Typhoid Fever
- Dietary Carbohydrates
- Carbohydrates
- Polymers
- Macromolecular Substances
- Polysaccharides
- Starch
- Glucans
- Biopolymers
- Fructans
- maltodextrin
- Inulin
- Ty21a typhoid vaccine
Other Study ID Numbers
Other Study ID Numbers
- FL113
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.